Live Breaking News & Updates on புள்ளிவிவரங்கள் விமர்சனம்|Page 4

Stay updated with breaking news from புள்ளிவிவரங்கள் விமர்சனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021


Share this article
Share this article
INDIANAPOLIS, March 17, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio
® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms of the study and measured their experiences with side effects, symptoms, and health-related quality of life, in those receiving Verzenio plus ET versus ET alone. In one analysis, the PRO data indicated that most patients (approximately 70-75%) in both arms reported being bothered a little bit or not at all by treatment-related side effects. This analysis revealed the addition of Verzenio to ET did not result in a clinically meaningful difference in patients reporting being bothered by treatment ....

United States , Saram Tolaney , Courtney Kasinger , Kevin Hern , Prnewswire Eli Lilly , Eli Lilly , Gallen International Breast Cancer Conference , World Health Organization , Harvard Medical School , Gallen International Breast Cancer Conference Poster , Lilly United States , Exchange Commission , Dana Farber Cancer Institute , Gallen International Breast Cancer , Dana Farber Cancer , Adjuvant Systemic Therapy , Standard Definitions , Efficacy Endpoints , For Grade , Prescribing Information , Private Securities Litigation Reform Act , United States Securities , Statistics Review , Natl Cancer , Adv Med , Eli Lilly And Company ,